← All Context Therapeutics INC filings

Context Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CNTX
Context Therapeutics INC
10-K: Context Therapeutics Advances Cancer Pipeline, Reports Increased Losses
Context Therapeutics Inc. reported a net loss of $36.1 million for 2025 as it advanced its bispecific antibody pipeline for solid tumors, with key clinical trial data expected in 2026.
NASDAQ
CNTX
Context Therapeutics INC
10-K: Context Therapeutics Reports 2024 Results, Advances Bispecific Antibody Pipeline
Context Therapeutics Inc. announces its 2024 financial results and provides updates on the clinical development of its T cell engaging bispecific antibody programs targeting solid tumors.
NASDAQ
CNTX
Context Therapeutics INC
10-K: Context Therapeutics Inc. Details Share Structure and Anti-Takeover Measures in 10-K Filing
Context Therapeutics Inc.'s 10-K filing outlines the company's share structure, voting rights, and measures designed to deter hostile takeovers.